Oncology (all articles)
Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: A meta-analysis beyond 10 years of follow-up.
31 May, 2022 | 11:47h | UTC
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/alex_ford12399/status/1527601814765551616
RCT: Rivaroxaban vs. placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.
31 May, 2022 | 11:19h | UTC
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
31 May, 2022 | 10:46h | UTC
Commentary on Twitter
Online Now: Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies https://t.co/Im8F60VMjO
— Cancer Cell (@Cancer_Cell) May 27, 2022
Retrospective Cohort Study | Ovarian cancer detection in average-risk women: classic- versus nonclassic-appearing adnexal lesions.
30 May, 2022 | 10:58h | UTCNews Release: Researchers use ultrasound to predict ovarian cancer – Radiological Society of North America
Commentary: Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy – HealthDay
Commentary on Twitter
Classifying adnexal lesion appearance as classic or nonclassic has high sensitivity and specificity for diagnosing malignancy in women at average risk for ovarian cancer. @BaranLab @drantil7 @kpatellippmann @katematuren @ayakamaya @hanna_zrad @LizSadowski https://t.co/6NphOIycMe pic.twitter.com/99DyWIHXwU
— Radiology (@radiology_rsna) March 28, 2022
10-yr follow-up of a phase 3 RCT: chemoradiotherapy in muscle-invasive bladder cancer.
30 May, 2022 | 10:52h | UTC
Commentary on Twitter
Chemoradiotherapy in MIBC: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trialhttps://t.co/x8EFIoiqla@Prof_Nick_James @ProfSyedHussain @robert_huddart @NPortaStat
"Long-term findings confirm the benefit of adding 5-FU and MMC to RT for MIBC" pic.twitter.com/bKWSWhwemB
— European Urology (@EUplatinum) May 19, 2022
M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.
30 May, 2022 | 10:41h | UTCStereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
Single-arm, phase II trial: overall survival and biomarker analysis of neoadjuvant Nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer.
30 May, 2022 | 10:39h | UTC
Commentary on Twitter
In NADIM study of neoadj chemo + nivo for stage IIIA NSCLC, 3-y OS was 91%; low levels of pretreatment ctDNA and undetectable ctDNA after neoadjuvant therapy were predictive of OS (with HRs of 0.07 and 0.04, respectively) https://t.co/BIprSnDICd
— NatureRevClinOncol (@NatRevClinOncol) May 18, 2022
Dairy consumption and risks of total and site-specific cancers in Chinese adults: an 11-year prospective study of 0.5 million people.
27 May, 2022 | 12:20h | UTCNews Release: Dairy products linked to increased risk of cancer – University of Oxford
Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds.
27 May, 2022 | 12:04h | UTCCommentary: Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds – The BMJ
Current guidelines in the surgical management of hereditary colorectal cancers.
27 May, 2022 | 12:00h | UTC
RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.
27 May, 2022 | 11:51h | UTCEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)
Commentary on Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Cohort Study: Age at initiation of lower gastrointestinal endoscopy and colorectal cancer risk.
27 May, 2022 | 11:26h | UTCAge at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women – JAMA Oncology (link to abstract – $ for full-text)
Commentaries:
Related:
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
ACG Clinical Guidelines: Colorectal Cancer Screening 2021 – The American Journal of Gastroenterology
Screening and prevention of colorectal cancer – The BMJ
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1522244731899629571
RCT: Tiragolumab plus atezolizumab vs. placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer.
27 May, 2022 | 11:11h | UTCTiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters
RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.
27 May, 2022 | 11:15h | UTCCommentaries:
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post
Commentaries on Twitter
A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx
— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022
First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2
— JAMA Oncology (@JAMAOnc) March 31, 2022
RCT: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer.
27 May, 2022 | 11:09h | UTCAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
26 May, 2022 | 10:57h | UTCRelated:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
26 May, 2022 | 10:30h | UTCSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1524781949386166272
RCT: Aumolertinib vs. Gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.
26 May, 2022 | 10:10h | UTC
Commentary on Twitter
Aumolertinib (a 3rd gen TKI) is effective in the first-line treatment of EGFR-mutant NSCLC-AENEAShttps://t.co/QL6xXptxFa pic.twitter.com/grIbapsxzU
— K Pavithran (@drkpavithran) May 18, 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/
RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.
25 May, 2022 | 11:49h | UTCEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
RCT: Everolimus is not beneficial when added to adjuvant endocrine therapy in patients with high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative primary breast cancer.
25 May, 2022 | 10:57h | UTC
Commentaries on Twitter
Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC
— Paolo Tarantino (@PTarantinoMD) May 24, 2022
Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO
— K Pavithran (@drkpavithran) May 24, 2022
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
RCT: Effect of Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer.
25 May, 2022 | 10:54h | UTCEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm
— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022
Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.
25 May, 2022 | 10:42h | UTC
ASCO Research Statement: Increasing racial and ethnic diversity in cancer clinical trials.
24 May, 2022 | 08:08h | UTC